ACTIVAERO FURTHER STRENGTHENS CYSTIC FIBROSIS COMPETENCE THROUGH NEW RESEARCH COLLABORATION WITH STANFORD UNIVERSITY
(Thomson Reuters ONE) -
Activaero GmbH /
ACTIVAERO FURTHER STRENGTHENS CYSTIC FIBROSIS COMPETENCE THROUGH NEW RESEARCH
COLLABORATION WITH STANFORD UNIVERSITY
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Gemuenden/Wohra, Germany, October 17, 2013 - Activaero GmbH, the therapeutic
area specialist for respiratory diseases focusing on novel, pharmacoeconomically
meaningful treatment solutions for severe lung diseases, today announced that it
has entered into a research collaboration with Stanford University, one of the
world's leading institutions for research and education. The parties are going
to jointly evaluate the potential of Activaero's flow and volume regulated
FAVORITE inhalation approach in the treatment of Cystic Fibrosis patients with
hypertonic saline compared to treatment with standard nebulizers.
The proof-of-concept study will specifically assess for changes in small airway
pulmonary function parameters after a therapy session of 7% hypertonic saline
delivered by a standard Pari-LC Jet nebulizer and FAVORITE inhalation as well as
differences in sputum production with each inhalational device. In addition,
differences in the tolerability of 7% hypertonic saline delivered with each
inhalational device will be monitored.
FAVORITE inhalation allows for optimum drug distribution across the entire lung
importantly including the small airways. This most distal region of the lung is
typically not accessible with standard nebulizer systems due to the obstructions
caused by scarred tissue and mucus in the lungs of Cystic Fibrosis patients.
"Besides our internal research focus on severe asthma, Activaero has always been
fully dedicated to improving the quality of life of patients suffering from
Cystic Fibrosis with its inhalation approach. As there are a variety of
therapeutic approaches to manage the symptoms and consequences of the disease,
we are investigating a whole portfolio of solutions together with high caliber
partners such as Stanford University", commented Gerhard Scheuch, Founder and
Chief Executive Officer of Activaero GmbH. "Currently, hypertonic saline
treatments are performed with conventional nebulizers delivering only a small
fraction of the solution to the small airways. A higher dose in the periphery of
the lungs may help improving lung function and sputum production."
About Cystic Fibrosis
Cystic Fibrosis (CF), also known as mucoviscidosis, is one of the most common
genetic disorders amongst Caucasians. The disease is inherited recessively with
an improved but still rather low life expectancy with a median age of currently
33.4 years according to the World Health Organization. CF leads to chronic
inflammations of the respiratory tract and also affects other organs, such as
the digestive tract, liver, sweat glands and reproductive organs. Symptoms
include heavily salty-tasting sweat, coughing similar to whooping cough, severe
bronchitis and pneumonia, an increased production of tough and viscous mucus
that leads to frequent bacterial infections as well as disturbed digestions and
male sterility. Most patients die from cardiorespiratory complications caused by
those symptoms.
About FAVORITE
FAVORITE is Activaero's proprietary, clinically and commercially proven
inhalation approach to effectively treat severe respiratory and pulmonary
diseases. FAVORITE actively regulates inspiration flow and inhalation volume. By
guiding, controlling and supporting the patient's breathing, optimal inhalation
patterns are created. Using FAVORITE, inhaled drugs can be selectively targeted
to pre-defined lung regions hence unlocking completely new opportunities for
novel aerosol therapies.
About Activaero
Activaero is a therapeutic area specialist developing new, pharmacoeconomically
meaningful treatment solutions for patients suffering from severe respiratory
diseases, including Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic
Fibrosis (CF), Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Hypertension.
Activaero was founded in 1998 in Germany and is a privately held company with
offices in Germany near Frankfurt and Munich as well as in Dublin, Ohio (USA).
www.activaero.de
About Stanford University
Stanford University is one of the world's leading research universities.
Stanford is known for its entrepreneurial character, drawn from the legacy of
its founders, Jane and Leland Stanford, and its relationship to Silicon Valley.
Research and teaching stresses interdisciplinary approaches to problem solving.
Areas of excellence range from the humanities to social sciences to engineering
and the sciences. Stanford is located in California's Bay Area, one of the most
intellectually dynamic and culturally diverse areas of the nation.
www.stanford.edu
Contact us:
Activaero GmbH Media Contact
Christian Pangratz Anne Hennecke
Chief Business Officer MC Services AG
t: +49-89-897969-65 t: +49-89-210228-18
e: christian.pangratz(at)activaero.de e: anne.hennecke(at)mc-services.eu
www.activaero.de
Press release (PDF):
http://hugin.info/156033/R/1736249/581830.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Activaero GmbH via Thomson Reuters ONE
[HUG#1736249]
Unternehmensinformation / Kurzprofil:
Datum: 17.10.2013 - 09:00 Uhr
Sprache: Deutsch
News-ID 306646
Anzahl Zeichen: 6491
contact information:
Town:
Gemuenden/Wohra
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ACTIVAERO FURTHER STRENGTHENS CYSTIC FIBROSIS COMPETENCE THROUGH NEW RESEARCH COLLABORATION WITH STANFORD UNIVERSITY"
steht unter der journalistisch-redaktionellen Verantwortung von
Activaero GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
